Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2003 Apr;12(2):89–94. doi: 10.1080/0962933031000097691

Interleukin (IL)-1 gene polymorphisms: relevance of disease severity associated alleles with IL-1beta and IL-1ra production in multiple sclerosis.

Hans M Schrijver 1, Jaco van As 1, J Bart A Crusius 1, Christien D Dijkstra 1, Bernard M J Uitdehaag 1
PMCID: PMC1781595  PMID: 12775358

Abstract

BACKGROUND: Multiple sclerosis (MS) is an autoimmune disorder, with a considerable genetic influence on susceptibility and disease course. Cytokines play an important role in MS pathophysiology, and genes encoding various cytokines are logical candidates to assess possible associations with MS susceptibility and disease course. We previously reported an association of a combination of polymorphisms in the interleukin (IL)-1B and IL-1 receptor antagonist (IL-1RN) genes (i.e. IL-1RN allele 2+/IL-1B(+3959)allele 2-) with disease severity in MS. Extending this observation, we investigated whether IL-1beta and IL-1ra production differed depending on carriership of this gene combination. METHODS: Twenty MS patients and 20 controls were selected based upon carriership of the specific combination. In whole blood, in vitro IL-1beta and IL-1ra production was determined by enzyme-linked immunosorbent-assay after 6 and 24 h of stimulation with lipopolysaccharide. RESULTS: Carriers of the specific combination produced more IL-1ra, especially in MS patients, although not significantly. IL-1ra production was significantly higher in individuals homozygous for IL-1RN allele 2. In patients, Il-1ra production was higher and IL-1beta production lower compared with controls. In primary progressive patients, the IL-1beta /IL-1ra ratio was significantly lower than in relapsing-remitting patients. CONCLUSION: Our results suggest higher in vitro IL-1ra production in carriers of IL-1RN allele 2, with an indication of an allelic dose-effect relationship.

Full Text

The Full Text of this article is available as a PDF (208.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arend W. P. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest. 1991 Nov;88(5):1445–1451. doi: 10.1172/JCI115453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bioque G., Crusius J. B., Koutroubakis I., Bouma G., Kostense P. J., Meuwissen S. G., Peña A. S. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol. 1995 Nov;102(2):379–383. doi: 10.1111/j.1365-2249.1995.tb03793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blakemore A. I., Tarlow J. K., Cork M. J., Gordon C., Emery P., Duff G. W. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum. 1994 Sep;37(9):1380–1385. doi: 10.1002/art.1780370917. [DOI] [PubMed] [Google Scholar]
  4. Brosnan C. F., Cannella B., Battistini L., Raine C. S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology. 1995 Jun;45(6 Suppl 6):S16–S21. doi: 10.1212/wnl.45.6_suppl_6.s16. [DOI] [PubMed] [Google Scholar]
  5. Danis V. A., Millington M., Hyland V. J., Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 1995 Feb;99(2):303–310. doi: 10.1111/j.1365-2249.1995.tb05549.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dyment D. A., Sadovnick A. D., Ebers G. C., Sadnovich A. D. Genetics of multiple sclerosis. Hum Mol Genet. 1997;6(10):1693–1698. doi: 10.1093/hmg/6.10.1693. [DOI] [PubMed] [Google Scholar]
  7. Feakes R., Sawcer S., Broadley S., Coraddu F., Roxburgh R., Gray J., Clayton D., Compston A. Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis. J Neuroimmunol. 2000 Jun 1;105(1):96–101. doi: 10.1016/s0165-5728(00)00203-4. [DOI] [PubMed] [Google Scholar]
  8. Hurme M., Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol. 1998 Aug;28(8):2598–2602. doi: 10.1002/(SICI)1521-4141(199808)28:08<2598::AID-IMMU2598>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  9. Kantarci O. H., Atkinson E. J., Hebrink D. D., McMurray C. T., Weinshenker B. G. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol. 2000 Jul 1;106(1-2):220–227. doi: 10.1016/s0165-5728(00)00202-2. [DOI] [PubMed] [Google Scholar]
  10. Mandrup-Poulsen T., Pociot F., Mølvig J., Shapiro L., Nilsson P., Emdal T., Røder M., Kjems L. L., Dinarello C. A., Nerup J. Monokine antagonism is reduced in patients with IDDM. Diabetes. 1994 Oct;43(10):1242–1247. doi: 10.2337/diab.43.10.1242. [DOI] [PubMed] [Google Scholar]
  11. Mann C. L. A., Davies M. B., Stevenson V. L., Leary S. M., Boggild M. D., Ko Ko C., Jones P. W., Fryer A. A., Strange R. C., Thompson A. J. Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. J Neuroimmunol. 2002 Aug;129(1-2):197–204. doi: 10.1016/s0165-5728(02)00181-9. [DOI] [PubMed] [Google Scholar]
  12. Nicoletti F., Patti F., DiMarco R., Zaccone P., Nicoletti A., Meroni P., Reggio A. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine. 1996 May;8(5):395–400. doi: 10.1006/cyto.1996.0054. [DOI] [PubMed] [Google Scholar]
  13. Pociot F., Mølvig J., Wogensen L., Worsaae H., Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest. 1992 Jun;22(6):396–402. doi: 10.1111/j.1365-2362.1992.tb01480.x. [DOI] [PubMed] [Google Scholar]
  14. Schrijver H. M., Crusius J. B., Uitdehaag B. M., García González M. A., Kostense P. J., Polman C. H., Peña A. S. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology. 1999 Feb;52(3):595–599. doi: 10.1212/wnl.52.3.595. [DOI] [PubMed] [Google Scholar]
  15. Sciacca F. L., Ferri C., Vandenbroeck K., Veglia F., Gobbi C., Martinelli F., Franciotta D., Zaffaroni M., Marrosu M., Martino G. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology. 1999 Jun 10;52(9):1896–1898. doi: 10.1212/wnl.52.9.1896. [DOI] [PubMed] [Google Scholar]
  16. Tarlow J. K., Blakemore A. I., Lennard A., Solari R., Hughes H. N., Steinkasserer A., Duff G. W. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993 May;91(4):403–404. doi: 10.1007/BF00217368. [DOI] [PubMed] [Google Scholar]
  17. Thompson A. J., Polman C. H., Miller D. H., McDonald W. I., Brochet B., Filippi M Montalban X., De Sá J. Primary progressive multiple sclerosis. Brain. 1997 Jun;120(Pt 6):1085–1096. doi: 10.1093/brain/120.6.1085. [DOI] [PubMed] [Google Scholar]
  18. Voltz R., Hartmann M., Spuler S., Scheller A., Mai N., Hohlfeld R., Yousry T. Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):200–201. doi: 10.1136/jnnp.62.2.200-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Yaqoob P., Newsholme E. A., Calder P. C. Comparison of cytokine production in cultures of whole human blood and purified mononuclear cells. Cytokine. 1999 Aug;11(8):600–605. doi: 10.1006/cyto.1998.0471. [DOI] [PubMed] [Google Scholar]
  20. de Jong Brigit A., Huizinga Tom W. J., Bollen Eduard L. E. M., Uitdehaag Bernard M. J., Bosma Gerlof P. Th, van Buchem Mark A., Remarque Edmond J., Burgmans Alexandra C. S., Kalkers Nynke F., Polman Chris H. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol. 2002 May;126(1-2):172–179. doi: 10.1016/s0165-5728(02)00056-5. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES